X4 Pharmaceuticals

Contributing Author

Recent Articles by X4 Pharmaceuticals

Aug-06	X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update XFOR XFOR +11.27% GlobeNewswire
Aug-06	X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update XFOR XFOR +11.27% GlobeNewswire
Aug-03	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
Jul-07	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
Jul-01	X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors XFOR -12.53% GlobeNewswire
Jun-01	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
May-27	X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference XFOR GlobeNewswire
May-06	X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update XFOR GlobeNewswire
Apr-29	X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union XFOR GlobeNewswire
Apr-01	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR +5.33% GlobeNewswire
Mar-17	X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update XFOR +18.82% GlobeNewswire
Mar-04	X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference XFOR +5.11% GlobeNewswire
Mar-02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
Feb-03	X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 XFOR GlobeNewswire
Feb-02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR +7.57% GlobeNewswire
Nov-05	X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference XFOR -10.58% GlobeNewswire
Nov-05	X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update XFOR -10.58% GlobeNewswire
Oct-27	X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million XFOR GlobeNewswire
Oct-24	X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering XFOR +22.98% GlobeNewswire
Oct-23	X4 Pharmaceuticals Announces Proposed Underwritten Public Offering XFOR GlobeNewswire
Sep-17	X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation XFOR -5.30% GlobeNewswire
Aug-15	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR -9.24% XFOR -12.63% GlobeNewswire
Aug-13	X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement XFOR +13.57% GlobeNewswire
Aug-12	X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership XFOR +81.69% GlobeNewswire
Jun-16	X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) XFOR GlobeNewswire
Jun-10	X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA XFOR -14.01% GlobeNewswire
Jun-02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR +12.06% GlobeNewswire
May-14	X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress XFOR XFOR -6.79% GlobeNewswire

X4 Pharmaceuticals

Recent Articles by X4 Pharmaceuticals

Upgrade your Finviz experience